Provided by Tiger Fintech (Singapore) Pte. Ltd.

Biocryst Pharmaceuticals

7.25
-0.2500-3.33%
Post-market: 7.250.00000.00%16:20 EDT
Volume:2.25M
Turnover:16.43M
Market Cap:1.51B
PE:-16.86
High:7.49
Open:7.46
Low:7.22
Close:7.50
Loading ...

BioCryst Pharmaceuticals Price Target Maintained With a $30.00/Share by HC Wainwright & Co.

Dow Jones
·
25 Feb

RBC Capital Adjusts Price Target on BioCryst Pharmaceuticals to $11 From $10, Keeps Outperform Rating

MT Newswires Live
·
25 Feb

BioCryst Pharmaceuticals Inc : Wedbush Initiates Coverage With Outperform Rating; Target Price $15

THOMSON REUTERS
·
25 Feb

BioCryst selloff yesterday brings buying opportunity, says JPMorgan

TIPRANKS
·
25 Feb

BioCryst Pharmaceuticals Full Year 2024 Earnings: EPS Misses Expectations

Simply Wall St.
·
25 Feb

Analysts Have Conflicting Sentiments on These Healthcare Companies: BioCryst (BCRX), Addus Homecare (ADUS) and Jazz Pharmaceuticals (JAZZ)

TIPRANKS
·
25 Feb

Q4 2024 BioCryst Pharmaceuticals Inc Earnings Call

Thomson Reuters StreetEvents
·
25 Feb

BioCryst Pharmaceuticals Inc (BCRX) Q4 2024 Earnings Call Highlights: Strong ORLADEYO Revenue ...

GuruFocus.com
·
25 Feb

BioCryst Pharmaceuticals (BCRX) Q4 2024 Earnings Call Transcript

Motley Fool Transcribing
·
25 Feb

BioCryst Pharmaceuticals Unveils Latest Trial Data, Reports Mixed Q4 Earnings

Benzinga
·
25 Feb

BioCryst Pharmaceuticals Shares Drop After Wider-Than-Expected 4Q Loss

Dow Jones
·
24 Feb

BUZZ-U.S. STOCKS ON THE MOVE-BioMarin, Azul, Sun Communities

Reuters
·
24 Feb

BUZZ-BioCryst falls on wider-than-expected quarterly loss

Reuters
·
24 Feb

Stock Track | BioCryst Pharmaceuticals Plummets 7% on Q4 Earnings Miss, Raises 2025 Revenue Outlook

Stock Track
·
24 Feb

BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Tops Revenue Estimates

Zacks
·
24 Feb

Stock Track | BioCryst Pharmaceuticals Soars 5.21% in Pre-Market on Strong Full-Year Outlook and Positive Pediatric Trial Results

Stock Track
·
24 Feb